Related Experiment Video
Updated: Aug 16, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Interaction between moclobemide and oral tyramine in depressed patients
1Department of Medicine, Wellington School of Medicine, New Zealand.
Abstract:
We investigated the pressor response to oral tyramine before and during treatment with moclobemide, a selective monoamine oxidase-A inhibitor, in 10 depressed patients. Before moclobemide therapy, tyramine was associated with a mean (SD) maximum rise in systolic blood pressure of 4.0 (5.2) mmHg, whereas during moclobemide treatment, tyramine was associated with an increase of 24.9 (14.2) mmHg. Only one subject failed to demonstrate an increased pressor response while taking moclobemide. Moclomebide potentiates the pressor response to oral tyramine, but is safer than older nonselective monoamine oxidase inhibitors.
More Related Videos
Related Concept Videos
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Therapeutic Drug Monitoring: Affecting Factors

